Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brontictuzumab for NOTCH1-mutated Adenoid Cystic Carcinoma
NCT02662608Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2015
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of brontictuzumab in adenoid cystic carcinoma (ACC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Participants With Disease Progression at 6 weeks. Started Dec 2015; status: completed.
02
Drugs
brontictuzumab
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT02662608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02662608.